NovoCure Limited: A Post Q2 Analysis

follows below Published on TradingView.com, Jul 26, 2024 08:08 UTC-4 NovoCure Limited, 1D, Cboe One 18.65 -0.14 (-0.75%) Vol. 2.048.M. 40.00 36.00 32.00 28.00 24.00 12.00 图 2024 "I"/ TradingView This is a wearable, portable, and FDA-approved glioblastoma (GBM) treatment for adult patients. The company is currently in late stage pivotal trial development utilizing Optune GIO concurrent with chemo radiation (TRIDENT, top-line results in 2026) and also with pembrolizumab to TTFields and temozolomide (KEYNOTE D ...